SHARPE
Reported results
- Revenue reached $410.1 million in the third quarter of 2026, an increase of 15.6% compared to the third quarter of 2025.
- Global thrombectomy revenue was $279.2 million in the third quarter of 2026, an increase of 18.1% compared to the third quarter of 2025.
- Gross profit margin was 68.3% in the third quarter of 2026, an increase of 0.5% compared to the third quarter of 2025.
- Total operating expenses were $229.6 million in the third quarter of 2026, including $7.1 million of acquisition-related expenses.
- Income from operations was $50.7 million and net income was $42.3 million in the third quarter of 2026.
Notes
Due to the pending acquisition of Penumbra, Inc. by Boston Scientific Corporation, the company is not providing full year 2026 financial guidance.
Price and volatility reaction
The stock moved -0.9% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved +14.0 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 321.97 | 2026-10-29 |
| Close after release | 318.95 | 2026-10-30 |
| Realised move | -0.9% | close to close |
| 30d ATM IV change | +14.0 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-10-29 (8-K, Item 2.02). Read the original filing on sec.gov.